Steminent Biotherapeutics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	0.94	0.64	2.12
Revenue Growth (YoY)	-	-	47.96%	-70.01%	-95.88%
Cost of Revenue	0.79	6.09	1.98	9.57	3.87
Gross Profit	-0.79	-6.09	-1.04	-8.93	-1.75
Selling, General & Admin	57.6	45.83	62.7	33.87	25.76
Research & Development	115.28	110.38	67.73	55.41	48.09
Operating Expenses	172.87	156.21	130.42	89.28	73.85
Operating Income	-173.66	-162.3	-131.46	-98.21	-75.6
Interest Expense	-2.15	-1.92	-1.78	-0.9	-1.33
Interest & Investment Income	2.51	4.13	2.96	0.85	0.07
Currency Exchange Gain (Loss)	-0.87	1.34	-0.02	2.8	-0.8
Other Non Operating Income (Expenses)	0.02	0.14	1.08	9.99	-46.1
EBT Excluding Unusual Items	-174.15	-158.6	-129.23	-85.47	-123.75
Gain (Loss) on Sale of Investments	-	-	-	-	-0.46
Gain (Loss) on Sale of Assets	-	-	-	-	0
Pretax Income	-174.15	-158.6	-129.23	-85.47	-124.2
Income Tax Expense	-0.11	0.15	-	-	-
Net Income	-174.04	-158.75	-129.23	-85.47	-124.2
Net Income to Common	-174.04	-158.75	-129.23	-85.47	-124.2
Shares Outstanding (Basic)	59	56	48	44	35
Shares Outstanding (Diluted)	59	56	48	44	35
Shares Change (YoY)	5.49%	15.42%	8.84%	26.27%	17.57%
EPS (Basic)	-2.95	-2.84	-2.67	-1.92	-3.52
EPS (Diluted)	-2.95	-2.84	-2.67	-1.92	-3.52
Free Cash Flow	-140.07	-226.57	-142.27	-71.52	-55.71
Free Cash Flow Per Share	-2.38	-4.05	-2.94	-1.61	-1.58
Gross Margin	-	-	-110.10%	-	-82.32%
Operating Margin	-	-	-13970.14%	-15442.14%	-3564.12%
Profit Margin	-	-	-13733.16%	-13439.31%	-5855.78%
Free Cash Flow Margin	-	-	-15119.02%	-11245.28%	-2626.69%
EBITDA	-155.03	-158.14	-129.51	-96.59	-71.91
D&A For EBITDA	18.63	4.15	1.95	1.62	3.69
EBIT	-173.66	-162.3	-131.46	-98.21	-75.6

Source: S&P Global Market Intelligence. Standard template. Financial Sources.